![]() |
Trials |
A phase I, open-label, multi-arm, multi-centre, multi-dose, dose escalation study of LTX-315 as monotherapy or in combination with either ipilimumab or pembrolizumab, in patients with transdermally accessible tumoursCancer type: Multiple diagnosis Phase: I Principal Investigator: Omenaas Ernst Country: NO Keywords: Norway, Bergen, Lytix, multiple diagnosis, LTX-315,Ipilimumab, prembolizumab Status: Inclusion completed Link to Clinicaltrials.gov: https://clinicaltrials.gov/ct2/show/NCT01986426?term=C12-315-03&rank=1 |